Objective To assess whether post-authorisation studies registered with the European Medicines Agency (EMA) adhere to legislation and recommendations to publicly post study protocols and results.
Cytokinetics CYTK reported a net loss of $1.50 per share for the fourth quarter of 2025, wider than the Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results